Summary To assess the role of insulin-like growth factors (IGFs) in growth and transformation of normal (myometrium) and tumorous smooth muscle cell (SMC) tissues, in situ hybridization (ISH) analysis for insulin-like growth factor and 11 (IGF-I and IGF-Il) mRNAs was combined with detection of IGF peptides, their receptors and IGF binding protein-3 (IGFBP-3). mRNAs for both IGFs were detected in smooth muscle cells in normal, benign and malignant SMC tissues, together with the IGF peptides, both IGF receptors and IGFBP-3. This suggests an autocrine role for both IGFs. Leiomyomas had higher IGF-I peptide levels and higher levels of type I IGF receptors than myometrium, supporting the idea that IGFs play a role in the growth and transformation of these tumours. Low-grade leiomyosarcomas contained more IGF-Il mRNAs than myometrium and leiomyoma, fewer type 11 IGF/mannose 6-phosphate receptors and less IGFBP-3 than myometrium and, in addition, fewer IGF-I mRNAs and type I IGF receptors than leiomyoma. Intermediate-and high-grade leiomyosarcomas had intermediate levels of IGF-Il mRNAs and peptide, ranging between those in myometrium and low-grade leiomyosarcomas. Thus, growth and transformation of leiomyosarcomas may be regulated by IGF-11, although more markedly in low-grade than in high-grade leiomyosarcomas. In conclusion, the various categories of SMC tissues are associated with a distinct expression pattern of the IGF system. This suggests that each category of SMC tumours arises as a distinct entity and that there is no progression of transformation in these tissues.
Transformation is a stepwise process in which cells proceed to a different phenotype because of genomic alterations. At the functional level, the transformed phenotype is characterized by one or more of the following features: immortalization, change in cell morphology, in vitro focus formation due to decreased contact inhibition, reduced in vitro requirement of serum growth factors, anchorage-independent growth (growth in soft agar) and in vivo tumorigenicity (Wharton and Smyth, 1989) . Transformation requires the activation of specific transformation signalling pathways. This is illustrated by the observation that type I insulin-like growth factor receptor-deficient fibroblasts, which have impaired growth capacity, acquire a transformed phenotype after transfection with ras, without reversal of the growth deficiencies Sell et al, 1994) . Thus, transformation is independent of increased cell proliferation, although unrestricted proliferation may be favoured with progressing transformation. Similarly, apoptosis and transformation are independent functions, although the apoptosis-inducing pathway may be blocked by the accumulation of genomic alterations, e.g. by the activation of the apoptosis blocking oncogene bc12 (Aaronson, 1991; Schmandt and Mills, 1993) .
Initiation of transformation may result from deregulated activity of any factor in transformation signalling pathways and thus may involve overstimulation with growth factors, enhanced receptor signalling and increased activity of second messengers and of nuclear binding proteins. Transforming growth factor x and , and platelet-derived growth factor BB are typical inducers of transformation in selected systems (Burgess, 1989; Heldin and Westermark, 1989; Hsuan, 1989) . In addition, transformation may result from decreased activity of transformation-inhibiting factors, known as products of anti-oncogenes or tumour-suppressor genes (Schmandt and Mills, 1993) .
The insulin-like growth factors (IGF-I and IGF-II) are polypeptide growth factors, which play an important role in cellular and somatic growth (Cohick and Clemmons, 1993) . Both IGFs can bind to the type I IGF receptor with similar affinity, whereas the type II IGF/mannose 6-phosphate receptor preferentially binds IGF-II. The type I IGF receptor mediates the mitogenic action of both IGFs (Nissley and Lopaczynski, 1991) , and the type II IGF receptor is mainly associated with differentiation and histomorphogenesis (Nissley and Lopaczynski, 1991) . IGF functions are modulated by IGF-binding proteins (IGFBPs), of which six distinct variants have been characterized (Drop et al, 1992) . At the cellular level, these IGFBPs may facilitate the binding of IGFs to their receptors or they may inhibit this binding (Jones and Clemmons, 1995) . Although IGFs are not designated as (proto)oncogene products, there are many indications that they have transformationinducing capacity. For instance, overexpression of the IGFs or of the type I IGF receptor is observed in many human tumours (Glick et al, 1989; Tommola et al, 1989; Merrill and Edwards, 1990; Macaulay, 1992) .
We have previously shown that higher IGF-I concentrations in leiomyoma than in myometrium may be as a result of the higher levels of type I IGF receptors in leiomyoma ( Van der Ven et al, 1994) . The increased responsiveness to IGF-I of cultured leiomyoma smooth muscle cells compared with their normal counterparts is in line with this observation. Furthermore, malignant transformation of smooth muscle tissues is associated with increased expression of IGF-II (Gloudemans et al, 1990) . In the present study, employing in situ hybridization for IGF-I mRNA, we analyse whether the increased levels of IGF-I in benign compared with normal smooth muscle cells could be of autocrine source. This series is completed with an analysis of malignant smooth muscle tissues. In these tissues, we also compare IGF-II mRNA hybridization signal, IGF-I and -II peptide concentrations, immunohistochemical localizations and staining intensities, and immunohistochemistry of both IGF receptors and of IGFBP-3 to find indications for a role of the IGF system during oncogenic transformation in these tissues.
MATERIALS AND METHODS Tissue collection
Normal and benign smooth muscle tissues were obtained from the uteri of patients that had undergone hysterectomy to treat leiomyoma. Informed consent was obtained according to the guidelines of the Dutch Cancer Foundation and the Ethical Council of the Utrecht University Hospital. Leiomyosarcomas were resected from a variety of organs. Specimens were collected from surgery as soon as possible. Part of the tissue was snap-frozen in liquid nitrogen and stored at -80°C for further use in mRNA or peptide extraction procedures and for immunohistochemistry.
Another part was routinely fixed in 4% phosphate-buffered formaldehyde (Klinipath, Duiven, The Netherlands), dehydrated through a graded ethanol/xylene series and embedded in paraffin. Data of the tissues that were included in this analysis are outlined in the Table. Most of the included tissues show positive staining for x-smooth muscle actin or desmin, confirming the smooth muscle phenotype. Loss of expression of smooth muscle markers in leiomyosarcomas is a common event in these tumours (Roholl et al, 1990 ). The shown percentage of necrosis was estimated on histological sections. A high necrotic index would bias the results from radioimmunoassays. Therefore, tumours with a high percentage of necrosis (>50%) were excluded from assays in which vitality of the tissue could not be checked. The protocol for use of the tissues in this study was approved by the Ethical Council of the Utrecht University Hospital.
Northern blotting analysis
The presented Northern blotting data are a revision of previous results (Gloudemans et al, 1990) . The original films were scanned in a densitometer, and scanning values of 7.6-kb IGF-I mRNA and of 4.8-and 6.0-kb IGF-II mRNA bands were corrected for exposure time. The Northern blotting analysis comprises the same tissue cohort, although more samples were processed for Northern blotting than for in situ hybridization. In the present analysis, the quantified Northern blotting results are rearranged according to the classification shown in the Table. In situ hybridization From the paraffinized tissues, 4-,im sections were prepared on aminopropyltriethoxysilane (Sigma Chemicals, St Louis, MO, USA) coated slides. Specific mRNAs were detected by subjecting the sections to an in situ hybridization procedure (Denijn et al, Klempt et al (1992) ; specificity for immunostaining of the polyclonal antisera for the type I and type II IGF receptors was demonstrated by Rosenzweig et al (1990) and by Couce et al (1992) respectively. The no. 3637 antiserum cross-reacts with the human type II IGF receptor (Gelato et al, 1988) . The IGFBP-3 antiserum recognizes the IGFBP-3 38.5-41.5-kDa bands and IGFBP-3 degradation products in an immunoblotting of human serum, but not IGFBP-2 and -4. In a radioimmunoassay, there is no cross-reactivity of the IGFBP-3 antiserum to IGFBP-1. Binding of IGFs to IGFBP-3 does not interfere with binding of the antiserum to IGFBP-3 (Bruning et al, 1995) . Preincubation of the IGFBP-3 antiserum with its antigen induced a reduction of immunostaining intensity of 50-90% in various normal and transformed smooth muscle tissues. Background staining was checked by omitting the primary antibody. The immunohistochemical procedure was described elsewhere ( Van der Ven et al, 1994) and includes preincubation with a normal serum, analogous to the species origin of the second antibody, incubation with the primary antibody and an appropriate biotinylated second antibody (together with the normal sera obtained from Vector, Burlingame, CA, USA). These steps were alternated with washes with phosphate-buffered saline (PBS)/Tween. The bound immune complex was visualized with horseradish peroxidase-avidin-biotin complex (Vector) . As a chromogenic substrate for the horseradish peroxidase, we used nickel-enhanced 3,3'diaminobenzidine (DAB, Merck). Nuclei were counterstained with nuclear fast red. Immunostained cells were dehydrated in ethanol/xylene and embedded in DePeX. Immunostained sections were examined by two independent observers for staining pattern (appearance and localization) and for staining intensity. Each independent antibody was scored subjectively in a range including absent or low (±), intermediate (+) and high (++) staining intensity. For each variable, results from duplicate observations with either the same or different antisera were pooled.
Radioimmunoassay (RIA)
For determination of IGF-I and IGF-II concentrations in the smooth muscle tissues, tissue extracts were prepared as described previously (D'Ercole and Underwood, 1987; Van der Ven et al, 1994) . IGF-binding proteins were eliminated from these extracts under acid conditions using C18 Sep-Pak cartridges (Sep-Pak, Waters, Milford, MA, USA; Van der Ven et al, 1994) , and IGFs were measured in a radioimmunoassay as described previously Van der Ven et al, 1994) . The results were expressed in ng ml-', using recombinant IGF-I (International Reference Reagent 87/518 from the National Institute for Biological Standards and Control, Potters Bar, Herts, UK) and native human IGF-II extracted in our own laboratory as the reference peptides respectively. For the IGF-I RIA, the intra-and interassay coefficients of variation were 5.9% and 7.9%, and for the IGF-II RIA these values were 7.0% and 7.7% (Bruning et al, 1995) . The lower detection limit was 0.005 ng per tube for IGF-I and 0.014 ng per tube for IGF-II.
Statistical analysis
Differences of levels of mRNAs and peptides of IGF-I and IGF-II among the four categories of tissues (normal, benign, low-grade malignant and intermediate-high-grade malignant) were tested for significance using a Student's t-test or in a Welch t-test when variances between groups departed significantly from homogeneity. Significance of difference of the observed distribution from a random distribution of immunohistochemical staining intensities for IGF-I, IGF-II, both IGF receptors or IGFBP-3 over the four categories of smooth muscle tissues was analysed in a chi-square test. Table) and a spot-wise pattern with regional intensity differences (right, case Fb in the Table) RESULTS Localization and quantification of IGF-I and IGF-II mRNA
In situ hybridization showed that in myometrium both IGF-I and IGF-II mRNAs are distributed in a whirling pattern, whereas the distribution in leiomyoma shows a more uniform pattern. This difference, illustrated for IGF-II in Figure IA , corresponds with the histology of these tissues. In leiomyosarcomas, the pattern of distribution is more variable. In Figure IB , both a diffuse distribution and a contrasting spot-wise signal distribution with regional intensity differences are illustrated. At higher magnification the signals for both IGF-I and IGF-II mRNAs emerge predominantly from smooth muscle cells (illustrated for IGF-II in Figure 2 ). A distinct difference between myometrium and leiomyoma is that the signal is uniformly distributed over all cells in the former tissue, whereas there are cell-dependent differences in signal intensity in the latter. The leiomyosarcoma in Figure 2C illustrates a high-intensity hybridization signal for IGF-II mRNA in smooth muscle cells.
Using a phosphor imager, the hybridization signal was quantified. At the level of IGF-I mRNA there are no differences among the four groups of tissues ( Figure 3A) . In situ hybridization for IGF-II mRNAs, however, shows significantly higher levels in lowgrade leiomyosarcomas than in myometrium and leiomyoma. However, there were no higher IGF-ll mRNA levels in intermediate-high-grade tumours, compared with normal myometrium or with low-grade tumours. The intensities of the hybridization signals show large variations between individual leiomyosarcomas, and these variations are different for IGF-I and IGF-II (not shown). This indicates the specificity of these respective signals.
In the present analysis, previously prepared Northem blottings are quantified and reclassified (see Materials and methods and Gloudemans et al, 1990) . Compared with the in situ hybridization signals ( Figure 3A) , Northern Figure 4A ). This nuclear staining is unexplained. Results with both IGF-I antisera were similar. Staining intensities were high in the cellular compartments of myometrium and leiomyoma and lower in the cellular compartments of most leiomyosarcomas ( Figure 3B ), representing a significantly asymmetrical distribution. Tissue concentrations of IGF-1, as determined by a radioimmunoassay, are summarized in Figure  3A . Mean Figure 4Q , with higher intensity in leiomyomas than in myometrium and leiomyosarcomas ( Figure 3B ). Immunostaining for the type II IGF receptor revealed positive staining, also in smooth muscle cells. Diffuse immunostaining was found over the cytoplasm (Figure 41) ). Staining intensity was similar in myometrium and leiomyoma, but there was a lower staining intensity in most leiomyosarcomas ( Figure 3B ). IGFBP-3 was visualized by immunohistochemistry in the cytoplasm of smooth muscle cells ( Figure 4E ), with higher intensity in myometrium and leiomyoma than in leiomyosarcoma ( Figure 3B ). As for IGF-II, immunostaining was concentrated in a perinuclear region. The distribution of staining intensities for both IGF receptors and for T1"_MD_'A r%,ty,,A-r tha frvivr t;,vcima ixy-ac e;ain;-Sinninflu ti;ffi-ri-nt from a random distribution. Figure 2 In situ hybridization for IGF-11 mRNA, illustrating that the signal emerges from smooth muscle cells. The signal is diffuse and with low intensity in myometrium (A); with cell-dependent intensity differences in leiomyoma (B); diffuse and with high intensity in a low-grade leiomyosarcoma (C); case B in the Table) . Illustrations of myometrium and leiomyoma are representative. Protocol as in Figure 1A ; tissue staining with haematoxylin-eosin. Scale (rec-2) , and IGFBP-3 (BP-3) is lower in both groups of leiomyosarcomas than in myometrium and leiomyoma. IGF-11 immunostaining is similar in all four categories of tissues. Significance of difference between the observed distribution and a random distribution of immunohistochemical staining intensities for each antigen over the four categories of smooth muscle tissues was analysed in a chi-square test. *P < 0.05, **P < 0.01
British Journal of Cancer (1997) The first question of this study addresses the site of production of IGFs in smooth muscle tissues. In all three categories of smooth muscle tissues -myometrium, leiomyoma and leiomyosarcoma -IGF mRNAs were predominantly detected in smooth muscle cells. This is in line with the distribution of IGF-I mRNA in uterine smooth muscle cells in rats (Ghahary et al, 1990) . Using immunohistochemistry, it could be demonstrated that IGF-II in smooth muscle cells predominantly results from endogenous production, because it is concentrated in a perinuclear region. Endogenous production as the major source for IGF-II is further supported by the concomitant peaks of mRNAs and peptide, as detected with radioimmunoassay, in low-grade leiomyosarcomas ( Figure 3A) . Cytoplasmic staining for IGF-I was more diffuse, compatible with endogenous production and endocytosis. The importance of binding and internalization of IGF-I is supported by concomitantly higher IGF-I peptide and type I IGF receptor levels in leiomyomas than in myometrium, without a change in IGF-I mRNA levels. There are no obvious changes in IGF-I mRNA levels, supporting IGF-I production.
The hybridization signal for IGF-I and -II mRNAs was found with equal intensity over all cells in myometrium. This may be a manifestation of a well-regulated IGF gene expression in this tissue, for which the oestrogenic cycle may be the regulating principle (Ghahary et al, 1990; Murphy, 1991; Kapur et al, 1992; Stevenson et al, 1994) . In contrast, individual cells in leiomyomas show large differences of IGF mRNA levels, indicating autonomous production of these mRNAs. Oestrogen-independent expression in leiomyomas has been reported for both IGF genes (Giudice et al, 1993; Vollenhoven et al, 1994) . Higher IGF-II mRNA levels in low-grade smooth muscle sarcomas than in myometrium also indicate autonomous production.
In conclusion, normal and transformed smooth muscle cells can produce both IGFs in vivo. Additional IGF-I enhances density of cultured smooth muscle cells (Van der Ven et al, 1994) . Thus, the IGFs may contribute to the stimulation of smooth muscle cell proliferation in vivo in an auto-paracrine mode of action, which is a regulated mechanism in normal uterus myometrium but not in transformed tissues.
Role of IGFs in transformation of smooth muscle tissues
The second object of this study was to determine the contribution of the IGF system to transformation and progression of transformation in smooth muscle tissues. A variable expression of the components of the IGF system was detected in the different categories of normal and benign smooth muscle tissues.
The higher levels of the type I IGF receptor in leiomyomas compared with myometrium ( Figure 3B ) were discussed previously as a cause for the detected higher IGF-I levels in leiomyoma compared with myometrium, because of higher IGF-I binding and endocytosis (Van der Ven et al, 1994) . Overexpression of type I IGF receptor may contribute also to transformation. This is suggested by the occurrence of increased type I IGF receptor levels in other tumours (Glick et al, 1989; Merrill and Edwards, 1990; Peyrat et al, 1990) , representing benign (meningioma) and malignant tumours (glioma, breast cancer). A direct oncogenic action of the type I IGF receptor was suggested by the induction of a (ligand-dependent) transformed phenotype in rodent and human fibroblasts due to overexpression of this receptor (Kaleko et al, 1990; Prager et al, 1994) . Conversely, blocking of type I IGF receptor production resulted in reversal of the transformed phenotype of several tumour cell lines (Resnicoff et al, 1994a, b; Long et al, 1995) and mouse embryo cells without type I IGF receptor are refractory to transformation by oncogenes (Sell et al, 1993) . In leiomyosarcomas, however, levels of the type I IGF receptor were similar to those in myometrium, and therefore a possible role for this receptor in transformation of smooth muscle cells seems to be restricted to benign transformation.
There was a continuous increase in IGF-II mRNA levels from myometrium to leiomyoma to low-grade leiomyosarcomas. This tendency was found with in situ hybridization and with Northern blot analysis. Higher levels of IGF-II mRNAs in leiomyomas were also reported by others (Vollenhoven et al, 1994) , and IGF-II overexpression has also been observed in other tumours (Antoniades et al, 1992; Macaulay, 1992; Ilvesmaki et al, 1993) . In five rhabdomyosarcomas, IGF-II expression was inversely proportional to the degree of differentiation (Yun, 1992) , but this finding is in contrast to the lower IGF-II expression in intermediate-high-grade leiomyosarcomas than in low-grade leiomyosarcomas in our study. The higher IGF-II expression in low-grade tumours may indicate a role for IGF-II as a tumour promoter, as was also suggested by the increased tumour incidence in IGF-II transgenic mice (Rogler et al, 1994) .
Compared with normal smooth muscle tissues, low-grade leiomyosarcomas show lower expression of IGF-I mRNA (Northern blotting), and all leiomyosarcomas show lower immunostaining intensity for IGF-I, type II IGF receptors and IGFBP-3. This may reflect a decrease of differentiation of these tumours, as suggested by the observed decrease of x-SMA (Table) and the reported decrease of smooth muscle markers associated with dedifferentiation in leiomyosarcomas (Roholl et al, 1988 (Roholl et al, , 1990 Fukuda et al, 1992) . Indeed, presence of type II IGF receptor was dependent on differentiation in other model systems (Cuthbertson et al, 1989; Szebenyi and Rotwein, 1991; Elliott et al, 1993) .
Differences of expression of components of the IGF system between leiomyomas and leiomyosarcomas are for the most part not continuous with those between myometrium and leiomyomas. This may be as a result of differences in origin, because none of the leiomyosarcomas included in this survey originated from the uterus, whereas all the leiomyomas did. Uterine leiomyomas are a particular category with respect to their frequent occurrence, compared with leiomyomas from other origins, but share cytogenetic aberrations with non-uterine leiomyomas (Mark et al, 1991) . Smooth muscle cells of uterine and non-uterine (blood vessels, gastrointestinal tract, lower urinary tract, vagina) origin share a responsiveness to oestrogen and/or progesterone (Wolf et al, 1991; Everson, 1992; Karas et al, 1994) , although there may be differences in expression of receptors for these hormones between smooth muscle cells of various parts of one organ. These features argue for the validity of comparing uterine leiomyomas with leiomyosarcomas from other origins.
In this comparison, it must be concluded that progressing transformation in smooth muscle tumours is associated with complex changes involving gain and loss of expression of various components of the IGF system. Distinct expression patterns of the IGF system are associated with different phenotypes of smooth muscle cell tissues, and therefore it is more likely that transformation to malignant smooth muscle tumours is not a proceeding process, but IGF system and smooth muscle transformation 1639 that each grade of smooth muscle tumour results from a distinct transformation event. In either case, in this model, the importance of the IGF system for tumorigenesis seems to be restricted to the lower grades of transformation.
